Nipro Medical Corporation Introduces State-of-the-Art ELISIO(TM)
Global Leadership in Design and Manufacturing Targets Better Dialysis
Patient Outcomes for U.S. Market
MIAMI, FL -- (Marketwired) -- 02/06/14 -- Nipro Medical Corporation,
a subsidiary for North & South America Sales and Marketing of Nipro
Corporation in Japan, a world leader in dialyzer design and
manufacturing, today announced the introduction of the ELISIO(TM)
Polynephron(TM) Single Use, High-Flux, Hollow-Fiber Dialyzer. The
ELISIO(TM) features a state-of-the-art Polynephron(TM) membrane
similar in function to that of a human kidney delivering outstanding
biocompatibility, hemocompatibility, and solute-removal performance,
resulting in superior clearances for better patient outcomes. The
ELISIO(TM) Polynephron Dialyzer has received 510(K) clearance from
the U.S. Food and Drug Administration (FDA). The product is designed
for the renal market, targeting those involved in care and procedures
for kidney disease and dialysis.
"Nipro dialyzers have been the preferred product for dialysis around
the globe for the past 30 years," said Joe Dawson, Senior Vice
President, Nipro North America. "The introduction of the ELISIO(TM)
dialyzer builds on our strategy of becoming a complete and
cost-effective dialysis solutions leader, offering blood tubing
lines, fistulas needles, and now dialyzers to our dialysis market
partners in the U.S. market. ELISIO(TM) is designed to deliver an
elevated benefits platform to the market, especially in clearance
performance of small to middle molecules, and it delivers on these
The sophisticated ELISIO(TM) membrane provides thousands of fibers
where each fiber acts like a nephron -- the functional unit of the
kidney, responsible for the actual purification and filtration of the
blood. A 3D chemical structure affords an ideal mixture of
hydrophilic and hydrophobic domains, while reducing membrane fouling
and maximizing membrane performance.
The ELISIO(TM) dialyzer's advanced pore-spinning technology creates
more homogenous pore sizes to optimize sieving properties. In
addition, the unique ripple structure in ELISIO's fiber creates less
dialysate channeling -- promoting better diffusive transport while
enhancing small molecule clearanc
es, and reducing the risk of fiber
"Both in-vitro and in-vivo testing have demonstrated the superior
clearance performance of the ELISIO(TM) dialyzer for both small and
middle molecules," Dawson said. "In addition, clinicians reported
excellent performance with regard to myglobin and B2 microglobulin,
and excellent biocompatibility on WBC and C5a."
The ELISIO(TM) dialyzer's inner design offers a very smooth
polyurethane cut surface that helps minimize the risk of blood cell
damage. An improved header shape reduces channeling at the blood
side, and the redesigned permanent caps eliminate the possibility of
unexpected removal or reuse.
"Innovative features that deliver better dialysis patient outcomes
are what Nipro has been delivering for more than 30 years," Dawson
said. "The ELISIO(TM) dialyzer builds on this performance promise."
The ELISIO(TM) Polynephron(TM) Single Use, High-Flux, Hollow-Fiber
Dialyzer is available in sizes from 90H to 250H. For complete
performance parameters and product specifications, or for more
information, visit www.nipro.com or call 1-305-599-7174.
About Nipro Medical: Nipro Corporation is a world-leading
manufacturer of Renal and Medical-Surgical products. The Company is
committed to educating customers and delivering innovative, high
quality and value-added solutions to improve patient care. Nipro
Medical Corporation is a wholly owned subsidiary of Nipro
Corporation, headquartered in Osaka, Japan.
For More Information, Contact:
Li Li Lee
Product Manager, North America
Nipro Medical Corporation
Press spacebar to pause and continue. Press esc to stop.